Edgewise Therapeutics Inc (NASDAQ: EWTX) has experienced a decline in its stock price by -0.19 compared to its previous closing price of 25.92. However, the company has seen a gain of 35.66% in its stock price over the last five trading days. benzinga.com reported 2024-09-25 that Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
The stock has a 36-month beta value of 0.18. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EWTX is 58.46M, and at present, short sellers hold a 13.97% of that float. On September 26, 2024, the average trading volume of EWTX was 1.21M shares.
EWTX’s Market Performance
EWTX’s stock has seen a 35.66% increase for the week, with a 28.13% rise in the past month and a 48.00% gain in the past quarter. The volatility ratio for the week is 10.01%, and the volatility levels for the past 30 days are at 7.75% for Edgewise Therapeutics Inc. The simple moving average for the past 20 days is 29.70% for EWTX’s stock, with a 53.35% simple moving average for the past 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Piper Sandler repeating the rating for EWTX by listing it as a “Overweight.” The predicted price for EWTX in the upcoming period, according to Piper Sandler is $48 based on the research report published on March 07, 2024 of the current year 2024.
Goldman gave a rating of “Sell” to EWTX, setting the target price at $5 in the report published on August 25th of the previous year.
EWTX Trading at 34.72% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.77% of loss for the given period.
Volatility was left at 7.75%, however, over the last 30 days, the volatility rate increased by 10.01%, as shares surge +30.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.53% upper at present.
During the last 5 trading sessions, EWTX rose by +35.66%, which changed the moving average for the period of 200-days by +276.56% in comparison to the 20-day moving average, which settled at $20.25. In addition, Edgewise Therapeutics Inc saw 136.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 75,000 shares at the price of $28.27 back on Sep 20 ’24. After this action, Russell Alan J now owns 12,719 shares of Edgewise Therapeutics Inc, valued at $2,120,101 using the latest closing price.
MOORE JOHN R, the General Counsel of Edgewise Therapeutics Inc, sale 50,000 shares at $28.37 during a trade that took place back on Sep 20 ’24, which means that MOORE JOHN R is holding 3,252 shares at $1,418,510 based on the most recent closing price.
Stock Fundamentals for EWTX
Current profitability levels for the company are sitting at:
- -60.47 for the present operating margin
- 0.09 for the gross margin
The net margin for Edgewise Therapeutics Inc stands at -51.46. The total capital return value is set at -0.26. Equity return is now at value -28.20, with -26.88 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.78. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -43.83.
Currently, EBITDA for the company is -112.62 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 1060.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.24.
Conclusion
To sum up, Edgewise Therapeutics Inc (EWTX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
